Virology
Major issues cloud interferon use in HIV and hepatitis C coinfected patients
Published in AIDS Weekly, May 16th, 2005
"We estimate that only one-third of patients coinfected with hepatitis C virus (HCV) and human immunodeficiency virus (HIV) are eligible for therapy for HCV with interferon (IFN) and ribavirin, and, of those who are eligible, two-thirds decline treatment. To date we have initiated treatment with IFN and ribavirin for 8% of coinfected patients evaluated, and <1% of patients have had a sustained virological response," according to investigators in the United States.
"During this process, we have identified many problems that significantly limit our ability to initiate and...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
Source: AIDS Weekly (2005-05-16)
More Articles from AIDS Weekly
- HIV/AIDS Diagnostics
Neutralizing/nonneutralizing IgG captures HIV-1 via antibodies against gp41 - HIV/AIDS Drug Development
Topological models predict anti-HIV activity of S-DABO analogues - HIV/AIDS Epidemiology
HIV non-B subtypes circulating in Italy - HIV/AIDS Tuberculosis Coinfection
HIV/TB patients have difficulty accessing ART outside Malawi hospital setting - Behavioral Medicine
Soccer program in Guinea helps girls avoid HIV/AIDS, pregnancy - Cancer Research
Cancer treatment shows encouraging clinical results in phase I/II trial - More from this issue of AIDS Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
